Decline of Mpox Antibody Responses After Modified Vaccinia Ankara–Bavarian Nordic Vaccination

JAMA

EMBARGOED FOR RELEASE: 11:30 A.M. ET, THURSDAY, OCTOBER 3, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.20951?guestAccessKey=bb14d353-976b-4703-883f-1d2cdabf8ec1&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=100324

 

About The Study: The modified vaccinia Ankara–Bavarian Nordic (MVA-BN) vaccination generated mpox antibodies that waned by 6 to 12 months. In participants who received 2 doses of MVA-BN vaccine, mpox antibody responses at 12 months were comparable to or lower than peak antibody responses in people receiving 1 dose, which provided limited protection.

 

Quote from corresponding author Dan H. Barouch, MD, PhD:

“In this observational study, we show that mpox antibody responses decline 6-12 months following Jynneos (MVA-BN) vaccination. Our data suggest that protective immunity may be waning in individuals who were vaccinated with this vaccine in 2022.”

 

Contact information for Dan H. Barouch, MD, PhD: email dbarouch@bidmc.harvard.edu.

 

(doi:10.1001/jama.2024.20951)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.